Kyprolis

Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were...


Data from a secondary analysis of the pivotal phase 3 ASPIRE trial that showed Carfilzomib ( Kyprolis ) for injection...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment...


Kyprolis ( Carfilzomib ) for Injection, a proteasome inhibitor, is approved for the treatment of patients with multiple myeloma who...


The medical journal Leukemia has published results from the Phase 2 trial known as PX-171-005, an open-label, multicenter clinical trial...


Results from a study published in Blood, the Journal of the American Society of Hematology ( ASH ), have demonstrated...


The FDA ( Food and Drug Administration ) has approved Kyprolis ( Carfilzomib ) to treat patients with multiple myeloma...


The Food and Drug Administration ( FDA ) has granted accelerated approval of Kyprolis ( Carfilzomib ) for injection, a...


Carfilzomib ( Kyprolis ) is a selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma....